BNP Paribas Asset Management
ELVN icon

BNP Paribas Asset Management’s Enliven Therapeutics ELVN Stock Holding History

BNP Paribas Asset Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.8K Sell
626
-218
-26% -$9.26K ﹤0.01% 1929
2026
Q1 		$33.1K Buy
844
+209
+33% +$5.79K ﹤0.01% 1877
2025
Q4 		$10K Buy
635
+158
+33% +$3.15K ﹤0.01% 2138
2025
Q3 		$10K Buy
477
+94
+25% +$1.9K ﹤0.01% 1627
2025
Q2 		$8K Buy
+383
New +$7.25K ﹤0.01% 1842

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

BNP Paribas Asset Management's ELVN Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Enliven Therapeutics (ELVN) stake by 26% in Q2 2026, selling an estimated $9.26K and leaving 626 shares worth $31.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1929.

BNP Paribas Asset Management first reported a position in ELVN in Q2 2025 and has held it in 5 quarters since. The position peaked at $33.1K in Q1 2026. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • BNP Paribas Asset Management held 626 shares of Enliven Therapeutics worth $31.8K as of Q2 2026.
  • BNP Paribas Asset Management sold 218 Enliven Therapeutics shares in Q2 2026, an estimated $9.26K.
  • Enliven Therapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1929 holding.
  • BNP Paribas Asset Management first reported a position in Enliven Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • BNP Paribas Asset Management's Enliven Therapeutics position peaked at $33.1K in Q1 2026.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.